Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

CinRx spinout launches to develop aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase inhibitor.

CinRx President and CEO Jon Isaacsohn told BioCentury the company acquired CIN-107

Read the full 516 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE